Annals of the ICRP Vol. 22/3
By
. ICRP
Description
In recent years much progress has been made in radiological methods, in dosimetry, and in the knowledge of radiation effects. The ICRP
has increased its risk estimates, and in addition, more extensive information has become available on the effect of age at exposure,
on gender differences, on the magnitude of risk and on the consequences on
in utero irradiation. It is therefore timely to review
the risks and benefits of research involving the exposure of humans to radiation. The objective of
Radiological Protection in Biomedical
Research is to provide advice to individuals planning such research, those involved in issuing general rules of conduct, and those
engaged in evaluation of specific research projects. The report should also be made available to those who may become the subject of
investigations (patients, volunteers). Published with this report is
Addendum 1 to ICRP Publication 53, Radiation Dose to Patients
from Radiopharmaceuticals. Published in 1987,
ICRP Publication 53 contained calculations on absorbed doses per unit activity
administered for some 120 radiopharmaceuticals in regular use at the time. The calculations were based upon biokinetic models and best
estimates of biokinetic data for individual radiopharmaceuticals. Since 1987 new radiopharmaceuticals have been introduced into regular
use. This addendum presents biokinetic and dosimetic data on six new radiopharmaceutics, and is intended to be part of a continuing process
of updating. Finally, a
Summary of the Current ICRP Principles for Protection of the Patient in Diagnostic Radiology is included
with the report. This has been prepared to encourage medical professionals to become aware of and to utilise those basic principles,
and is an update of a previous summary that appeared in
ICRP Publication 57 (1989).
Included in series
International Commission on Radiological Protection
